The Human CD8 Coreceptor Effects Cytotoxic T Cell Activation and Antigen Sensitivity Primarily by Mediating Complete Phosphorylation of the T Cell Receptor ζ Chain*
暂无分享,去创建一个
Andrew K. Sewell | David A. Price | Bent K. Jakobsen | P. Rod Dunbar | J. Bell | S. J. Dawson | R. Phillips | A. Sewell | M. Purbhoo | J. Boulter | B. Jakobsen | C. Hourigan | P. Dunbar | Rodney E. Phillips | Kara Olson | A. Vuidepot | Jonathan M. Boulter | Christopher S. Hourigan | John I. Bell | Anne-Lise Vuidepot | Marco A. Purbhoo | Sara J. Dawson | Kara Olson | D. Price | R. Phillips
[1] Philip J. R. Goulder,et al. Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.
[2] A. O'Rourke,et al. Cytotoxic T-lymphocyte activation involves a cascade of signalling and adhesion events , 1992, Nature.
[3] B M Baker,et al. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. , 1999, Immunity.
[4] P. Allen,et al. Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation. , 1998, Science.
[5] P. Marrack,et al. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. , 1998, Immunity.
[6] Y. Chien,et al. CD4 augments the response of a T cell to agonist but not to antagonist ligands. , 1997, Immunity.
[7] A. Smolyar,et al. Structural Basis of CD8 Coreceptor Function Revealed by Crystallographic Analysis of a Murine CD8αα Ectodomain Fragment in Complex with H-2Kb , 1998 .
[8] T. Greten,et al. MHC-based diagnostics and therapeutics - clinical applications for disease-linked genes. , 1999, Immunology today.
[9] P. A. Peterson,et al. CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes , 1996, Nature.
[10] W. Fung-Leung,et al. Thymic selection of cytotoxic T cells independent of CD8 alpha-Lck association. , 1993, Science.
[11] R. Phillips,et al. Antagonism of cytotoxic T lymphocyte‐mediated lysis by natural HIV‐1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides , 1997, European journal of immunology.
[12] J. Altman,et al. Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]. , 1998, Immunity.
[13] J. Yewdell,et al. Quantitating presentation of MHC class I-restricted antigens. , 2001, Methods in molecular biology.
[14] P. Parham,et al. The antigenic structure of HLA-A2: an analysis with competitive binding assays and monoclonal antibodies. , 1983, Journal of immunology.
[15] Z Reich,et al. Ligand recognition by alpha beta T cell receptors. , 1998, Annual review of immunology.
[16] P. Parham,et al. Cell-cell adhesion mediated by CD8 and MHC class I molecules , 1988, Nature.
[17] C. Tournay,et al. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding , 2000, Nature Medicine.
[18] B K Jakobsen,et al. TCR binding to peptide-MHC stabilizes a flexible recognition interface. , 1999, Immunity.
[19] D. Fremont,et al. High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. , 1998, Immunity.
[20] P. Allen,et al. Partially Phosphorylated T Cell Receptor ζ Molecules Can Inhibit T Cell Activation , 1999, The Journal of experimental medicine.
[21] S. Rowland-Jones,et al. Antigen–specific release of β-chemokines by anti-HIV-1 cytotoxic T lymphocytes , 1998, Current Biology.
[22] J. Bell,et al. BirA enzyme: production and application in the study of membrane receptor-ligand interactions by site-specific biotinylation. , 1999, Analytical biochemistry.
[23] P. Romero,et al. CD8 modulation of T-cell antigen receptor–ligand interactions on living cytotoxic T lymphocytes , 1995, Nature.
[24] P. Klenerman,et al. Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[25] B K Jakobsen,et al. Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. , 2000, Immunology today.
[26] Paul M. Allen,et al. Partial T cell signaling: Altered phospho-ζ and lack of zap70 recruitment in APL-induced T cell anergy , 1994, Cell.
[27] B. Walker,et al. β-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans , 1998, Nature.
[28] R. Germain,et al. Partial signaling by CD8+ T cells in response to antagonist ligands , 1996, The Journal of experimental medicine.
[29] B K Jakobsen,et al. T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics. , 1999, Immunity.
[30] G. Ogg,et al. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. , 1999, Journal of immunology.
[31] R. Phillips,et al. Patterns of Immunodominance in HIV-1–specific Cytotoxic T Lymphocyte Responses in Two Human Histocompatibility Leukocyte Antigens (HLA)-identical Siblings with HLA-A*0201 Are Influenced by Epitope Mutation , 1997, The Journal of experimental medicine.
[32] C. Janeway,et al. Both high and low avidity antibodies to the T cell receptor can have agonist or antagonist activity. , 1994, Immunity.
[33] N. Shastri,et al. Requirement for association of p56 lck with CD4 in antigen-specific signal transduction in T cells , 1991, Cell.
[34] P. Cresswell,et al. NK susceptibility varies inversely with target cell class I HLA antigen expression. , 1987, Journal of immunology.
[35] A. Hamad,et al. Potent T Cell Activation with Dimeric Peptide–Major Histocompatibility Complex Class II Ligand: The Role of CD4 Coreceptor , 1998, The Journal of experimental medicine.
[36] R. Zamoyska,et al. Is CD8 dependence a true reflection of TCR affinity for antigen? , 1993, International immunology.
[37] L. Samelson,et al. Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists , 1995, Science.
[38] V. Appay,et al. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. , 2001, Immunity.
[39] S. Jameson,et al. Critical Role for Cd8 in T Cell Receptor Binding and Activation by Peptide/Major Histocompatibility Complex Multimers , 2000, The Journal of experimental medicine.
[40] David I. Stuart,et al. Classical and Nonclassical Class I Major Histocompatibility Complex Molecules Exhibit Subtle Conformational Differences That Affect Binding to CD8αα* , 2000, The Journal of Biological Chemistry.
[41] G. Gao,et al. Antagonism of cytotoxic T-lymphocyte activation by soluble CD8 , 1999, Nature Medicine.
[42] J. Tschopp,et al. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production. , 1998, Journal of immunology.